Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 65-70

  Verhaar Langereis, M ^a   Karakus, A ^a   Van Eijkeren, M ^a   Voest, E ^a   Witteveen, E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Liposomal doxorubicin; Ovarian cancer; Platinum resistant ovarian cancer; Topotecan

Indexed keywords

DOXORUBICIN; PLATINUM; TOPOTECAN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TOPOTECAN; TREATMENT OUTCOME;

EID: 33645328297     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00298.x     Document Type: Article

References (25)

1. Jemal A Murray T Samuels A et al. Cancer statistics. CA Cancer J Clin 2003 53 5.
2. McGuire WP Ozols R. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998 25 340 8.
3. McGuire WP Hoskins WJ Brady M et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334 1 6.
4. Piccart MJ Bertelsen K Stuart G et al. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Oc Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience [abstract]. Proc Am Soc Clin Oncol 1997 16 352a. Abstract 1258.
5. Ozols RF Rubin S Dembo SC Robboy S. Epithelial ovarian cancer. In Hoskins WJ Perez CA Young RC eds. Principles and practice of gynaecologic oncology. Philadelphia, PA Lippincott 1992.
6. Herrin VE Thigpen T. Recent developments in the treatment of recurrent ovarian carcinoma. Adv Oncol 2000 16 21 9.
7. Markman M Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992 10 513 4.
8. Anzai H Frost P Abbruzzesse JL. Synergistic cytotoxicity with combined inhibition of topoisomerase topo I and II [abstract]. Proc Am Soc Clin Oncol 1992 11 431.
9. Ryan WR Fleming GF Janisch L. A phase I study of liposomal doxorubicin (doxil) with topotecan. Clin Oncol 2000 23 297 300.
10. Jonsson E Friborg H Nygren P Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998 54 509 14.
11. Yeung AW Wong M. Phase 1 trial of doxil and topotecan in solid tumours [abstract]. Proc Proc Am Soc Clin Oncol 1998 979.
12. WHO. Handbook for reporting results of cancer treatment. Geneva, Switzerland World Health Organization 1979.
13. Rustin GJS Quinn M Thigpen T et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004 96 487 8.
14. Gehan EA Schneiderman MA. Experimental design of clinical trials. In Holland JF Frei E III. eds. Cancer medicine. Philadelphia, PA Lea and Febiger 1982 531 53.
15. Voest EE Verhaar MJ. A phase II study of the combination doxil/caelyx and topotecan in platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 2001.
16. Gordon AN Fleagle JT Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 19 3312 22.
17. Bookman MA Malmstrom H Bolis G. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998 16 3345 52.
18. Ten Bokkel Huinink W Gore M Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 15 2183 93.
19. ™) in recurrent ovarian cancer. Cancer Treatm Rev 2002 28 121 5.
20. Tolcher AW O'Shaughnessy JA Weiss RB et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997 3 755 60.
21. Geertsen P Stroyer I Herrstedt J Hansen SW. A study of topotecan (T) and pegylated liposomal doxorubicin (caelyx) in patients with progressive ovarian cancer within 12 months after first-line platinum-paclitaxel containing chemotherapy [abstract]. Proc Am Soc Clin Oncol 2001. Abstract 2522.
22. Bookman MA Malmstrom H Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998 16 3345 52.
23. Von Pawel J Gatzemeier U Hartstrick M et al. A multicentre randomised phase II study of oral topotecan versus iv topotecan for second line therapy in sensitive patients with small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999 18 1816. Abstract.
24. Gore M Oza A Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002 38 57 63.
25. Penson RT Seiden MV Goodman A et al. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mullerian malignancies. Gyn Oncol 2004 93 702 7.